Prototype strategy for vaccines and antibodies to rubulaviruses

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: William Paul Duprex
Organization: WASHINGTON UNIVERSITY
Fiscal Year: 2024
Award: $5,674,171
Funding agency: National Institute of Allergy and Infectious Diseases

Project 2: Abstract
Rubulaviruses are respiratory pathogens with a high level of transmissibility (R0 = 4-7). MuV is an ideal prototype
pathogen to study paramyxoviruses because we have a human vaccine that elicits protective humoral immunity
directed to undefined target(s). P2-Rubulaviruses dissects the structure and functions of the F and HN
glycoproteins in entry and as antigens. The goal is to identify a general strategy for stabilization of the pre-fusion
form of the F glycoprotein and move this and the HN glycoprotein forward, either individually or in complex as
vaccine candidates using established in vivo models. In Aim 1 rational antigen design builds upon existing head
domain structure of HN adding regions of the stalk and generates new structures of stabilized, pre-fusion F
glycoprotein. This is augmented by cryoelectron tomography (Cryo-ET) to study the interactions of the native
F/HN complex on the virion. The immunogenicity of individual and glycoprotein pairs will be assessed in vivo to
iteratively inform design, and the results tested in divergent rubulaviruses. In Aim 2 we isolate single B cells from
vaccines and characterize the mAbs to further inform immunogen design. The mechanism of action of the mAbs
will be assessed in vitro using a combination of assays including virus-cell and cell-cell fusion. Their individual
and synergistic activities will be determined and ability to protect animals from infection and disease evaluated
in a cotton rat respiratory system model. Genetic barriers to escape from neutralization will be defined to reveal
how rapidly resistance mutations are acquired and their location(s) in the glycoproteins. Extension of this work
by immunization of a humanized mouse with bat mumps (BatMuV) will extend the findings to related
rubulaviruses considered to represent “pre-spillover” pathogens poised with pandemic potential. Lead
immunogens are evaluated in Aim 3 for in vivo for efficacy as soluble-adjuvated proteins, mRNAs and within the
context of a replication-competent rVSV-expressing both glycoproteins. Identification of correlates of protection
will facilitate iterative analysis of next generation immunogens and may identify an optimal platform. The
P2-Rubulaviruses project has exceptionally strong synergy with P1-Respiroviruses which will rapidly enable
go/no-go decision making and contribute to down-selection and prioritization of mAbs and immunogens for a
pathway to industrial translation. Similarly, the cross-talk between the data obtained from these two projects
using the three vaccine platforms will be useful to drive existing and develop new collaborations with partners in
industry.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Animal Disease Models><Animals><Antibodies><Antibody Response><Antigenic Determinants><Antigens><Assay><Attenuated Vaccines><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Bats><Binding><Binding Determinants><Bioassay><Biochemical><Biologic Models><Biological Assay><Biological Models><Biology><COVID-19 vaccine><COVID-19 virus><COVID19 virus><Cell Body><Cell fusion><Cells><Chiroptera><Clinical Treatment Moab><CoV-2><CoV2><Collaborations><Complex><Coronaviridae><Coronavirus><Cotton Rats><Cryo-electron tomography><Data><Decision Making><Development><Disease><Disorder><Educational workshop><Epidemic Parotitis><Epidemic Parotitis Virus><Epitope Mapping><Epitopes><Evaluation><Genetic><Glycoproteins><Goals><Head><Hu-mABs><Human><Humoral Immunities><Immune Globulins><Immunity><Immunization><Immunoglobulins><In Vitro><Individual><Industrialization><Industry><Infection><Knowledge><Lead><Length><Licensing><Live-attenuated Vaccine><Location><Messenger RNA><Mice><Mice Mammals><Model System><Modeling><Modern Man><Molecular><Molecular Interaction><Monoclonal Antibodies><Mumps><Mumps virus><Murine><Mus><Myxovirus parotitidis><NIAID><National Institute of Allergy and Infectious Disease><P variolae><P. variolae><P.variolae><Paramyxoviridae><Paramyxovirus><Pathway interactions><Pb element><Poxvirus variolae><Proteins><Pulmonary Body System><Pulmonary Organ System><Reagent><Receptor Protein><Regimen><Resistance><Respiratory System><Respiratory Tracts><Respiratory tract structure><Respirovirus><Rubulavirus><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Series><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Smallpox virus><Species Specificity><Structure><Structure-Activity Relationship><Test Result><Testing><Therapeutic antibodies><Transgenic Organisms><Translating><Translations><Transmission><Vaccinated><Vaccine Antigen><Vaccines><Variola major virus><Variola virus><Virion><Virus><Virus Particle><Work><Workshop><Wuhan coronavirus><Zoonoses><Zoonotic><Zoonotic Infection><antibody-based immunity><chemical structure function><corona virus><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><cryo-EM tomography><cryoEM tomography><cryoelectron tomography><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><electron cryo-tomography><epidemic parotiditis><hCoV19><heavy metal Pb><heavy metal lead><humAbs><human mAbs><human monoclonal antibodies><human monoclonals><humanized mice><humanized mouse><immunization strategy><immunogen><immunogenicity><in vivo><in vivo Model><iterative design><lipid based nanoparticle><lipid nanoparticle><live vaccine><live vaccines><mAbs><mRNA><monoclonal Abs><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neutralizing mAb><neutralizing monoclonal antibodies><next generation><pandemic><pandemic concern><pandemic containment><pandemic control><pandemic disease><pandemic disease preparedness><pandemic mitigation><pandemic planning><pandemic potential><pandemic preparedness><pandemic readiness><pandemic response><pandemic risk><pandemic threat><pathogen><pathogen spillover><pathway><pre-pandemic><protective efficacy><prototype><receptor><resistance mutation><resistant><resistant mutation><respiratory pathogen><small pox virus><structure function relationship><sugar><synergism><transgenic><translation><transmission process><vaccination strategy><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine antibodies><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine development><vaccine for novel coronavirus><vaccine induced antibodies><vaccine platform><vaccine strategy><vaccine-induced antibodies><vaccines preventing COVID><vaccines to prevent COVID>